|
Friday 1st February 2002 |
Text too small? |
Genesis posted a $9.6 million loss, in line with its 2000 float forecast of $9.1 million. It presented a "bright side" by emphasising it had $47.9 million in cash, down from $61 million a year ago.
"All that demonstrates is that they've burned another $13 million of cash without generating any additional revenue," one analyst commented. Revenue fell $8.7 million to $20 million.
CEO Jim Watson said the company had reached agreement with the US Food and Drug Administration on the next phase of trials of its PVAC psoriasis vaccine.
No comments yet
CHI - Government diesel storage at Marsden Point
April 20th Morning Report
NZK Market Update - Earnings Guidance Upgrade
MEL - Meridian Energy monthly operating report for March 2026
April 17th Morning Report
CCC - ESQUIRES IRELAND RECOGNISED AS THE BEST IN IRISH AWARDS
FBU - Fletcher Building Quarterly Volume Report for Q3 FY26
April 16th Morning Report
SCT - 2026 Half Year Announcement
Devon Funds Morning Note - 14 April 2026